Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection.
Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di Carlo P, Titone L, Bocchino M, Galati D, Matarese A, Nouta J, Klein MR, Salerno A, Sanduzzi A, Dieli F, Ottenhoff TH. Caccamo N, et al. Among authors: guggino g. PLoS One. 2009;4(5):e5528. doi: 10.1371/journal.pone.0005528. Epub 2009 May 13. PLoS One. 2009. Retraction in: PLoS One. 2019 Sep 19;14(9):e0223028. doi: 10.1371/journal.pone.0223028. PMID: 19436760 Free PMC article. Retracted.
Tuning inflammation in tuberculosis: the role of decoy receptors.
Di Liberto D, Caccamo N, Meraviglia S, Guggino G, La Manna MP, Sireci G, Salerno A, Dieli F. Di Liberto D, et al. Among authors: guggino g. Microbes Infect. 2009 Sep;11(10-11):821-7. doi: 10.1016/j.micinf.2009.05.004. Epub 2009 May 18. Microbes Infect. 2009. PMID: 19450705 Free article. Review.
Gammadelta T cell modulation in anticancer treatment.
Caccamo N, Dieli F, Meraviglia S, Guggino G, Salerno A. Caccamo N, et al. Among authors: guggino g. Curr Cancer Drug Targets. 2010 Feb;10(1):27-36. doi: 10.2174/156800910790980188. Curr Cancer Drug Targets. 2010. PMID: 20088797 Review.
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F. D'Asaro M, et al. Among authors: guggino g. J Immunol. 2010 Mar 15;184(6):3260-8. doi: 10.4049/jimmunol.0903454. Epub 2010 Feb 12. J Immunol. 2010. PMID: 20154204
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC. Meraviglia S, et al. Among authors: guggino g. Clin Exp Immunol. 2010 Aug;161(2):290-7. doi: 10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10. Clin Exp Immunol. 2010. PMID: 20491785 Free PMC article. Clinical Trial.
202 results